Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 25, 2018
Event: Entry into a Material Definitive Agreement (Underwriting Agreement) for an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Shares Offered (Firm): 6,500,000 shares of Common Stock.
- Public Offering Price: $5.00 per share.
- Price to Company: $4.70 per share (net of underwriting discounts).
- Expected Net Proceeds: Approximately $30.1 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 975,000 additional shares.
Material Changes
The filing reports the execution of an underwriting agreement with Piper Jaffray & Co. on January 25, 2018. This represents a material change in the company's capital structure and liquidity position pending the closing of the transaction. The filing does not provide comparative financial data against prior periods as it is a transactional report, not a periodic financial statement.
Outlook, Risks, and Management Commentary
- Closing Date: Expected on January 29, 2018, subject to customary closing conditions.
- Use of Proceeds: The filing text does not explicitly state the specific intended use of the net proceeds, though such details are typically found in the referenced prospectus supplement.
- Risks: The transaction is subject to customary closing conditions and termination provisions outlined in the Underwriting Agreement.
- Emerging Growth Company: The registrant is identified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 29, 2018).
- Confirm whether the underwriter exercises the option to purchase the additional 975,000 shares.
- Review the full Prospectus Supplement (referenced in the filing) for the specific intended use of the approximately $30.1 million in net proceeds.
- Check subsequent filings for the actual net proceeds received versus the estimated amount.